Precision BioSciences, Inc. has updated its corporate deck, providing key information on its clinical programs. The ELIMINATE-B study for chronic hepatitis B showed that PBGENE-HBV directly eliminated cccDNA, leading to a 1-log reduction in cccDNA-derived transcripts. The company is targeting year-end 2026 for the next program update related to PBGENE-HBV. The FUNCTION-DMD clinical trial, evaluating PBGENE-DMD for Duchenne muscular dystrophy, has activated a second clinical site at Washington University School of Medicine. Initial safety data for the FUNCTION-DMD trial is also targeted for year-end 2026.